Gyre Therapeutics(GYRE) - 2025 Q4 - Annual Results

Revenue Performance - Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range[1] - Full year 2026 revenue guidance is set at $100.5 to $111.0 million, representing a decline of approximately 13.8% to 4.8% compared to 2025[15] - Sales of ETUARY® reached $106.1 million for the full year 2025, compared to $105.0 million in 2024[5] - Revenues for Q4 2025 were $37.2 million, a 33.5% increase from $27.9 million in Q4 2024[30] - Total revenues for the year 2025 reached $116.6 million, up 10.4% from $105.8 million in 2024[30] Expenses and Financials - Selling and marketing expenses for the full year 2025 were $65.2 million, an increase of $7.7 million or 13.4% year-over-year[14] - Research and development expenses for the full year 2025 totaled $13.7 million, up from $12.0 million in 2024[14] - Operating expenses for Q4 2025 were $37.1 million, compared to $27.2 million in Q4 2024, reflecting a 36.4% increase[30] - Net income for the full year 2025 was $9.9 million, down from $17.9 million in 2024, a decrease of $8.0 million[17] - The company reported a net loss of $1,366 million for the three months ended December 31, 2025, compared to a net income of $569 million for the same period in 2024[34] - For the full year 2025, the company reported a net loss of $9,880 million, down from a net income of $17,898 million in 2024[34] - Non-GAAP adjusted net income for the three months ended December 31, 2025, was $4,268 million, up from $1,145 million in the prior year[34] - Non-GAAP adjusted net income for the full year 2025 was $18,886 million, compared to $16,882 million in 2024[34] - The total stock-based compensation for the full year 2025 was $7,157 million, significantly higher than $831 million in 2024[34] - The provision for income taxes for the three months ended December 31, 2025, was $1,300 million, compared to $203 million in the same period of 2024[34] - The provision for income taxes for the full year 2025 was $4,556 million, compared to $5,320 million in 2024[34] Clinical Trials and Product Development - Completed patient enrollment in the 52-week Phase 3 pirfenidone trial with 272 patients across 18 sites[4] - Hydronidone has completed Phase 3 clinical evaluation for chronic hepatitis B-associated liver fibrosis in China[21] - Hydronidone U.S. Investigational New Drug (IND) application anticipated in 2026, with NDA submission for conditional approval expected in the first half of 2026[1][2] - Gyre Pharmaceuticals is developing treatments for multiple conditions, including chronic obstructive pulmonary disease and pulmonary arterial hypertension[23] - Gyre received Breakthrough Therapy designation for Hydronidone from the NMPA CDE in March 2021[23] Acquisition and Cash Position - The company announced an agreement to acquire Cullgen for approximately $300 million, expected to close in Q2 2026[7] - Cash position as of December 31, 2025, was $75.9 million[8] - Cash and cash equivalents increased to $37.1 million in 2025 from $11.8 million in 2024[31] - Total assets grew to $166.1 million in 2025, up from $125.4 million in 2024, representing a 32.4% increase[31] Stock and Fair Value Adjustments - The gain from the change in fair value of warrants was a loss of $263 million for Q4 2025, compared to a loss of $194 million in Q4 2024[34] - The company continues to adjust its financials based on the Black-Scholes option pricing model for fair value of warrants[34] - Stock-based compensation increased significantly to $4,597 million in Q4 2025 from $567 million in Q4 2024[34]